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Both biomedical research and clinical practice rely on complex datasets for the physiological and genetic characterization of human hearts in
health and disease. Given the complexity and variety of approaches and recordings, there is now growing recognition of the need to embed
computational methods in cardiovascular medicine and science for analysis, integration and prediction. This paper describes a Workshop on
Computational Cardiovascular Science that created an international, interdisciplinary and inter-sectorial forum to define the next steps for a
human-based approach to disease supported by computational methodologies. The main ideas highlighted were (i) a shift towards human-
based methodologies, spurred by advances in new in silico, in vivo, in vitro, and ex vivo techniques and the increasing acknowledgement of the
limitations of animal models. (ii) Computational approaches complement, expand, bridge, and integrate in vitro, in vivo, and ex vivo experimental
and clinical data and methods, and as such they are an integral part of human-based methodologies in pharmacology and medicine. (iii) The
effective implementation of multi- and interdisciplinary approaches, teams, and training combining and integrating computational methods with
experimental and clinical approaches across academia, industry, and healthcare settings is a priority. (iv) The human-based cross-disciplinary
approach requires experts in specific methodologies and domains, who also have the capacity to communicate and collaborate across disci-
plines and cross-sector environments. (v) This new translational domain for human-based cardiology and pharmacology requires new partner-
ships supported financially and institutionally across sectors. Institutional, organizational, and social barriers must be identified, understood and
overcome in each specific setting.
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Motivation
Both biomedical research and clinical practice rely on complex da-
tasets for the physiological and genetic characterization of human
hearts in health and disease. The information shaping our knowledge
of human hearts is obtained from a variety of techniques and mod-
els, including recordings obtained in vivo invasively and non-
invasively, in ex vivo tissue and isolated human adult cardiomyocytes
recordings, and more recently in vitro using human stem-cell-derived
cardiomyocytes. Increasing evidence suggests that non-human ani-
mal models may have limited ability to predict human in vivo effects
due to important species differences between humans, dogs, guinea
pigs, and rabbits.1–3 Thus, methods firmly rooted in understanding
physiology and pathophysiology in humans are clearly needed.
Advances in imaging technologies such as the multiple modalities
of cardiac magnetic resonance (CMR) are combined with body sur-
face or intra-cardiac electrophysiological recordings to evaluate in
specific patients the in vivo structural and functional implications of
cardiac disease. Recent progress in research using human cardio-
myocytes derived from induced pluripotent stem cells promises ex-
citing new developments as it allows the in vitro characterization of
the phenotype of cardiomyocytes of specific patients, and therefore
has the potential of introducing the flexibility of in vitro methodolo-
gies in personalized medicine. Furthermore, ex vivo tissue from biop-
sies or from donor human hearts provides measurements of tissue,
cellular, and ionic properties of human adult cardiomyocytes in non-
diseased and diseased conditions.
Each of these types of human-based assays and measurements
provides us a single snapshot from one perspective of a complex
set of variables through both time and spatial dimensions. In turn,
this complex set of variables is able to define and explain the myriad
of dynamic mechanisms and properties that underlie the activity of
human hearts in health and disease. Given the complexity and var-
iety of approaches and recordings, there is now growing recognition
of the need to embed computational methods in cardiovascular
medicine and science for analysis, integration, and prediction. Com-
putational approaches in biomedicine range over a variety of techni-
ques for signal, data, and image analysis, but also importantly
multiscale modelling and simulation. Together, they provide a syner-
gistic approach to organize and augment the information obtained
from experimental and clinical recordings. The benefits gained in-
clude the quantitative analysis and organized reassembly of multi-
scale and multimodality datasets to probe, challenge and expand
our knowledge of the complex and dynamic interactions in cardiac
electrophysiology. Advances in computational cardiac electrophysi-
ology were recently illustrated in two dedicated special issues of
Europace 2014.4,5 Furthermore, new initiatives such as the Compre-
hensive in vitro Proarrhythmia Assay (CiPA) launched by the United
States Food and Drug Administration (FDA) recognize the potential
of human-based in silico and in vitro approaches as a new paradigm for
drug safety assessment.6
On 17 September 2014, a Workshop on Computational Cardio-
vascular Science was hosted at the University of Oxford with the
aim of creating an international, interdisciplinary, and inter-sectorial
forum to discuss current trends in computational technologies to
augment cardiovascular physiology, pharmacology, and medicine,
and to propose solutions for the replacement, refinement and
reduction of animal experimentation.7 Invited participants included
experts in cardiology, computer science, physiology, pharmacology,
philosophy, and biomedical engineering from academia and industry,
from 11 Universities and 12 companies, from UK, several countries
in Europe, USA, and Japan. In this paper, we aim at describing the
main ideas discussed during the meeting, rather than providing a
thorough review of the literature. Table 1 summarizes the forms
of human-based in vivo, ex vivo, in vitro, and in silico experiments
and techniques discussed, which are further illustrated in Figure 1.
The main ideas highlighted through the workshop were the
following:
† A shift towards human-based methodologies in pharmacology
and medicine is occurring, spurred by advances in new in silico,
in vivo, in vitro, and ex vivo techniques and the increasing acknowl-
edgement of the limitations of animal models.
† Computational approaches complement, expand, bridge, and in-
tegrate in vitro, in vivo, and ex vivo experimental and clinical data
and methods, and as such they are an integral part of human-
based methodologies in pharmacology and medicine.
† The effective implementation of multi- and interdisciplinary ap-
proaches, teams, and training combining and integrating compu-
tational methods with experimental and clinical approaches
across academia, industry, and healthcare settings is a priority.
† The human-based cross-disciplinary approach requires experts in
specific methodologies and domains, who also have the capacity
to communicate and collaborate across disciplines and to work
productively in interdisciplinary and cross-sector environments.
† This new translational domain for human-based cardiology and
pharmacology requires new partnerships supported financially
and institutionally across pharma and biotech industry, contract
research organizations (CRO), academia and research institutes,
technology and service providers, non-profit and governmental
organizations, and regulatory agencies. Institutional, organization-
al, and social barriers must be identified, understood, and over-
come in each specific setting.
Description of the workshop
The workshop consisted of four sessions aiming at exploring differ-
ent aspects of human-based cardiovascular science, and specifically
the synergies with in silico approaches in the three main experimen-
tal settings, i.e. in vivo, in vitro, and ex vivo. Table 1 summarizes the
forms of experiments and techniques discussed.
Human in vivo cardiovascular science
Prof. Peter Taggart examined the challenges involved in obtaining
basic electrophysiological data from in vivo human subjects, during
routine clinical procedures. The example discussed was the applica-
tion of percutaneous transluminal coronary angioplasty (PTCA) to
study in vivo the effect of myocardial ischaemia (a major cause of
mortality) on human electrophysiology, by recording either mono-
phasic action potentials or unipolar electrograms on the ventricular
endocardium in the region served by the artery undergoing PTCA.
In vivo electrophysiological recording techniques include the use of
the multi-electrode sock (264 electrodes) over the human ventri-
cles to study global patterns of activation such as ventricular
B. Rodriguez et al.Page 2 of 12
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fibrillation, action potential duration (APD) changes, and post-
repolarization refractoriness during early ischaemia and the demon-
stration of mechano-electric feedback in humans.10 – 20 Findings
addressed the debate as to whether rotors or multiple wavelets
drive ventricular fibrillation (VF) and showed that both coexist in
human VF, and the very rapid time course of the early electrophysio-
logical changes during early ischaemia in humans. In vivo electro-
physiological recordings are critical for translational research
(from basic to clinical) but they are limited due to considerations
for patient comfort and safety. Therefore, they need to be
complemented by and combined with alternative ways of probing
the human heart, including non-invasive in vivo imaging as well as
ex vivo investigations, as described below.
Dr Rina Ariga provided an overview of multimodality magnetic
resonance imaging and its application in patients with hypertrophic
cardiomyopathy (HCM). HCM is the most common genetic heart
disease (affects 1 in 500)21 and the commonest cause of sudden car-
diac death in the young.22 Transthoracic echocardiography (TTE) is
routinely used to assess HCM, but is limited in patients with poor
acoustic windows or poor visualization of some LV regions. CMR
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Summary of human-based in vivo, ex vivo, and in vitro techniques and in silico approaches
Human-based Data acquisition technique Limitations of the data Progress of in silico approaches
In vivo Electrophysiological recordings during
clinical procedures
[Taggart, Zhou]
– Limited data sets due to
ethical and practical
obstacles;
– Datasets derived from
diseased hearts;
– Inter-patient variability;
– Limited experimentation
– Signal analysis and integration;
– Multiscale electrophysiological models and
simulations;
– Population of models to mimic action potential
variability
Multimodality imaging including
magnetic resonance
[Ariga, Grau]
– Limited data sets;
– No experimentation
– Image analysis (tissue characterization);
– Ventricular shape analysis;
– Structural models and simulations
– Computer models for link between structure and
diffusion;
– And link between micro structure and function
Body surface potentials,
electrocardiogram
[Minchole, Lu]
– Captures global patterns
of heart behaviour;
– Variability
– Automated quantification of ECG features for clinical
diagnosis and identification of new bioamarkers
(morphological QRS or T-wave based, iCEB);
– Electrocardiographic imaging;
– Multiscale human heart simulations from ion channel
and microstructure to the electrocardiogram
mHealth recordings through mobile
devices
[Oster]
– Very large quantities of data
not amenable to manual
analysis;
– Noisy and patchy data;
– Social, ethical and legal
challenges
– Automated and semi-automated techniques for
analysis, such as machine learning, implementable on
mobile phones
Isolated human primary cells and
non-clinical, real-world data from
biopsies and medical histories
[Ghetti]
– Limited data sets;
– Social, ethical and legal
challenges
– Computational models to integrate experimental
data and to investigate multiscale mechanisms of
disease and pharmacological interventions
Ex vivo Microelectrode, optical mapping, patch
clamp, protein, and mRNA
expression
[Varro, Britton, Dutta]
– Limited availability, and
mostly from diseased
hearts;
– Variability;
– Difficulty of technique
implementation (cell
isolation; current
separation);
– Change of properties due
to cell isolation
– Data analysis and integration;
– Multiscale models for greater contextualization;
– Investigation of variability through approaches such
as population of models
In vitro Human cardiomyocytes derived from
induced pluripotent stem cells
(hiPSC-CMs)
[Daniels, Severi, Kopljar, Harmer]
– Inconsistent immaturity;
– Variability and associated
difficulty of comparison
– Models to investigate variability, assist interpretation,
and facilitate translation to in vivo cells
– Models to investigate gene mutations;
– Models for drug safety assessment
Cell cultures and high-speed optical
imaging
[Burton]
– Limited cross-institution
and cross-sector access to
experiments
– Multiscale modelling to explain dynamics in
heterogeneous preparations
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is now the gold standard in assessing mass, hypertrophy, volume,
and function in HCM due to high spatial and temporal resolution.23
Unlike TTE, CMR also provides tissue characterization using late
gadolinium enhancement (detects focal fibrosis which has been as-
sociated with ventricular arrhythmias and SCD)24 and T1 mapping
(detects diffuse and focal fibrosis). CMR also offers insights into sev-
eral hallmark features of HCM that are potential contributors of dis-
ease progression using novel techniques such as stress perfusion
imaging (impaired perfusion),25 blood oxygen level dependent
(BOLD) imaging at stress (deoxygenation at stress),26 phosphorus
MR spectroscopy (abnormal myocardial energetics at rest with fur-
ther deficit in exercise),27 and most recently, diffusion tensor im-
aging (to assess fibre disarray).28 CMR is not only a useful imaging
adjunct in cases with limited TTE views, but also provides accurate
disease characterization of subtle differences. Research using CMR
is improving our understanding of this complex heterogeneous dis-
ease and is helping to guide risk stratification and treatment
strategies.29
Prof. Vicente Grau spoke about methods to investigate myocar-
dial microstructure, including quantification using imaging as well as
determination of functional repercussions of microstructural
changes, investigated using computational modelling and simulation.
Recent developments in MRI technology, in particular using diffusion
sensitive sequences, allow the quantification of microstructure, ini-
tially in fixed hearts8,30,31 or in hearts at different stages of contrac-
tion.32 Diffusion MRI uses an indirect measurement to estimate
cardiac structure, and its relationship to cardiac microstructure is
not fully understood. Two methods to improve this understanding
were discussed. Histology offers direct insights into microstructure,
but three-dimensional reconstruction from histological slices is
Body
 Body surface potentials
 ECG recordings
 mHealth data
Arrhythmic-risk biomarkers
High-resolution
arrhythmia mechanisms
Atrial and ventricular
electrophysiology models
in health and disease
1
0.5
0
−0.5
0 200 400
Time (ms)
600
Potential
2.00
1.38
0.75
0.12
−0.50Organ
 Clinical EP Studies
 Multi-modality clinical MRI
Tissue
 High-resolution MRI
 Histology
 Optical mapping
 Cell cultures
Single cell
 Microelectrode recordings
 Protein/mRNA expression
 Optical mapping
Ionic current
 Voltage/patch clamp
 Isolated cells/hiPSC-CMs
Figure 1 Sources of experimental data integrated in computational models of human cardiac electrophysiology, and applications in physiology.
Ionic current models are constructed mostly based on voltage/patch clamp data from ex vivo and in vitro preparations. The integration of ionic
currentmodels in single cell models, accounting for variability in protein expression and disease remodelling, allows for the simulation of the action
potential and electrolyte concentrations in healthy and disease. Additionally, cardiac simulations at the whole organ and body levels require the
construction of image-based anatomical models. When coupled to mathematical descriptions of electrical excitation through cardiac tissue, they
allow for the high-resolution investigation of arrhythmia mechanisms based on clinical electrophysiology studies, as for the interpretation and
identification of arrhythmic-risk biomarkers at the surface potential level. Transmural visualization of ventricular myofibre orientation, adapted
from reference 8 with permission. ECG/whole body simulation, adapted from reference 9 with permission.
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challenging.33 Computational models, simulating water diffusion and
MRI acquisition sequences, can be used to provide a direct link be-
tween structure and diffusion.34 The relationship between micro-
structural and functional changes is not fully understood, and here
computational models can again provide a unique tool as shown
for example in references.35–37
In addition to imaging, clinical in vivo recordings to evaluate the hu-
man heart include the surface electrocardiograms (ECGs), a rapid
and cost-effective method to acquire non-invasive recordings. A
large body of research has been devoted to the quantification of
ECG features for patient stratification in terms of arrhythmic risk
and disease.38 Dr Ana Minchole´ described computational ap-
proaches applied to the ECG for the detection of electrophysio-
logical abnormalities and patient stratification in HCM. Using a
database of Holter recordings obtained in HCM patients and volun-
teers, she described the quantification of standard ECG-based bio-
markers such as QT T peak to T end, as well as new mathematical
model-based morphological features of the QRS complex and
T wave morphology.39,40 Dr Minchole also described how informa-
tion about the electrophysiological and structural signature of dis-
ease from the ionic to the whole organ level can be integrated in
multiscale human heart models and used in the development and
understanding of ECG-based biomarkers.41 Multiscale simulations
as illustrated in Figure 2 allow the identification of key structural
and functional factors that determine each of the ECG biomarkers
and provide a deeper and more precise understanding of the infor-
mation each of the biomarkers conveys.42 The new knowledge also
aids in the identification of more selective and specific biomarkers
for specific disease conditions with complex functional and struc-
tural signatures such as HCM or myocardial infarction. Body surface
ECGs combined with imaging data using mathematical algorithms
to non-invasively reconstruct the electrical activity on the epicardial
surface of the heart in vivo as demonstrated for example in
references.43–45
Human ex vivo and in vitro
cardiovascular science
Prof. Andras Varro began by discussing the knowledge we have of
human electrophysiology largely through classic techniques such
as conventional microelectrode and more modern patch clamp
techniques, protein and RNA expression approaches using human
cardiomyocytes from biopsies or donor hearts.46 – 48 Obtaining
good representative experimental human data is restricted by a
number of practical problems. Sources of tissue particularly ven-
tricular cells are difficult to obtain and isolation of cells is compli-
cated by disease. The source of undiseased donor hearts is
particularly limited. The process of cell isolation may also lead to
changes from properties studied in multicellular tissue preparations.
Furthermore, the separation of each of the ionic currents illustrated
in Figure 3 is problematic since the available pharmacological inhibi-
tors are not totally selective. Finally, Prof. Varro highlighted the im-
portance of human-based studies rather than highlighted the use of
animal models. It is often underappreciated that there are substan-
tial species differences between human and even large mammals,
such as the dog, considered to be a representative model.49,50 For
example, marked differences in ventricular repolarization reserve
have been reported between human and dog,49 with larger rapid
component of the delayed rectifying current (IKr) in human but
stronger slow component (IKs) and inward rectifying current (IK1)
0.4–0.8
mV
I
0.226 0.3 0.4
gks (nS/pF)
0.5 0.586 –0.4
–1 1
0 0.8
Figure 2 Computer simulation of the human heart electrophysiology from ion channel to body surface potentials and the electrocardiogram.
Simulations are conducted using human biophysically detailed models considering heterogeneity in specific ionic properties (left, colour scale cor-
respond to the maximum conductance of the slow component of the delayed rectifying current) to determine their effect on the spatiotemporal
evolution of electrical potentials across the whole torso (middle, extracellular potentials throughout the torso) and on the ECG (right, main leads
displayed).
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in the dog. Consequently, APD prolongation caused by selective IKr
block is three-fold larger in human than in dog, which suggests cau-
tion in translation of animal findings to human. Species-specific dif-
ferences in pharmacological action between animal models have
been also described,50 with rabbit exhibiting larger APD prolonga-
tion and proneness to repolarization abnormalities upon selective
IKr block compared to others. Computational modelling and simula-
tion can facilitate interspecies comparison by identifying and addres-
sing differences and maximizing the re-use of experimental data
from human hearts.
Dr Oliver Britton described how the complex electrophysio-
logical datasets obtained from ex vivo human hearts have been inte-
grated in multiscale computer models, specifically focusing on
human data over the past decade51–54 as examples. He described
the recent construction of a population of human ventricular cell
computational models that captures the inter-subject variability
seen in action potential recordings from human ventricular tissue
preparations from Prof Varro’s laboratory. The models in the popu-
lation have a wide range of different configurations of ionic current
strengths to mimic variability in a population as in reference 55. The
team investigated whether there were configurations that were par-
ticularly vulnerable to developing repolarization abnormalities such
as alternans and early afterdepolarizations (EADs), in response to
blockade of different combinations of currents known to be import-
ant in repolarization—rapid delayed rectifying (IKr), slow delayed
rectifying (IKs), inward rectifying (IK1), and late calcium (ICaL) current.
The computational approach therefore integrates and extends ex-
perimental recordings, generating predictions and refining hypoth-
eses about proarrhythmic mechanisms that can then be tested
experimentally. Importantly, the in silico human models provide a
multiscale framework to investigate with high spatiotemporal reso-
lution key ionic mechanisms in drug safety and efficacy in human,
with high degree of flexibility in the possible interventions (such
as heart rate, concentrations, and adrenergic challenge) compared
to experiments.
Prof. Matt Daniels reviewed the status of human cardiomyocytes
derived from induced pluripotent stem cells (hiPSC-CMs). He saw
three uses for these cells:
† screening for cardiotoxicity of novel therapeutics,
† modelling and drug discovery for inherited cardiac conditions and
† in the medium to long term, regenerative cell therapy.
While there is progress in scaling up production of these cells,56
functional maturity is still a major impediment. Stem cell derivatives
in many ways (force generation, gene expression, sarcomeric matur-
ity, electrophysiological properties, etc.) resemble immature neo-
natal cardiac substrates.57 However, there is one key difference
that is rather unique to these cells and best illustrated by compari-
son to the existing alternatives. Adult cardiomyocytes are consist-
ently mature; neonatal cardiomyocytes are consistently immature.
By contrast, stem cell derivatives display an inconsistent immaturity
(Figure 4) such that in any experimental test to date, variability within
the sample is typically one order of magnitude of measures such as
APD and cycle length as shown in reference 58. This will complicate
comparisons between samples, which are typically made on small
numbers of cells.
Dr Stefano Severi showed how a computational approach can be
supportive and complementary to the functional in vitro study of
hiPSC-CMs. In exploiting hiPSC-CMs as in vitromodels for the elec-
trophysiological effects of evolving or new drugs, a detailed under-
standing of the electrophysiological properties of hiPSC-CMs is
necessary. In silico models of hiPSC-CMs action potential have
been constructed for control60 and some genetic mutations, such
as those causing long QT (LQT) syndrome type 1 (LQT1),61 type
2, and type 3,62 based on recent electrophysiological measure-
ments63–66 and validated against drug administration. Computer si-
mulations showed that in principle hiPSC-CMs are qualitatively
consistent with adult CMs in response to many current blockers,67
but differences also emerged. Moreover, hiPSC-CMs show a highly
variable electrophysiological behaviour, namely a variable and depo-
larized resting potential and diverse rates of spontaneous action
50
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Figure 3 Simulation of the human ventricular action potential
and the underlying ionic currents. From top to bottom, time
course of the action potential, sodium current (INa), L-type calcium
current, the rapid and slow component of the delayed rectifying
current (IKr, IKs) and the inward rectifying current (IK1), the transi-
ent outward current (Ito) and the sodium potassium pump (INaK)
and the sodium calcium exchanger (INaCa).
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potentials. Such high variability can be perceived as a limiting factor
to the application of the computational approach to hiPSC-CMs. In-
deed, computational models of cell electrophysiology are usually
developed on the basis of the average values of quantities measured
in in vitro experiments. The underlying idea is that the predictions
obtained with the model of the ‘average cell’ can apply to all the cells
with a tolerance that is of the same order of the variability of the
data on which the model is based. Therefore, high variability in
the data results in predictions with lower reliability. One way to
overcome this limitation is to include the variability within the model
itself (which is no longer a model of the ‘average cell’) in order to
take it into account both in the investigation of physiological me-
chanisms and in model-based predictions. The aforementioned
population of models approach is a relevant and promising example.
Furthermore, when experimental data show high variability, com-
putational models can help to identify the causes of such hetero-
geneity and potentially help to reduce it. As a relevant example,
computational analysis can be used to assess towhat extent the vari-
ability is due to (i) different experimental systems (e.g. cell lines) that
could then be described by different, specific, computational models
(ii) differences in the expression of ionic channels from cell to cell,
which is eventually much larger than in adult cardiomyocytes or (iii)
lack of robustness in the electrical activity of incompletely mature
hiPSC-CMs. An example of the latter case are the effects of small
changes in depolarizing currents, which can lead to dramatic
changes in the rate of spontaneous beating in hiPSC-CMs, whereas
they lead to only minor changes in resting potential in adult cardio-
myocytes. In this sense, the variability can be reduced if observed in
the model parameter’s space since cells showing very different APs
could be quite close in terms of their ionic current maximal
conductances.
Dr Ivan Kopljar continued the theme looking at experimental
studies on hiPS-CMs in safety assessments in the drug development
setting, with an emphasis on the investigation of long-term drug
Variable expression
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Figure 4 Stem-cell-derived cardiomyocytes have variable phenotypes: current methods of stem cell differentiation produce mixed populations
at two distinct levels—gene expression, and post-transcription. This is demonstrated for sarcomeric morphology here, with the panel on the left
showing two cells in the field of view positive for the z-disc marker alpha-actinin (white), and the thin filament protein troponin I (magenta). How-
ever, further heterogeneity exists even within the cell populations expressing both markers, as only some cells demonstrate ordered sarcomeric
units with clear cell polarity (panel on the right). Methods to eliminate (or compensate for) this will be needed to enable small differences between
samples to be identified above the noise of the difference within the sample. Scale bar 10 mm. The human ES line OXF2 was grown to confluency
on Matrigel and differentiated as described in reference 59. Cells were dissociated by incubation with trypsin/EDTA (0.05%, Lifetech) for 15 min at
room temperature prior to seeding onto 0.1% gelatin coated glass coverslips. Ten days after seeding, cells were fixed in 4% PFA (10 min, room
temperature), permeabilized (0.1% Triton X-100 in Tris-buffered saline), and blocked with 2% BSA plus 0.001% sodium azide in TBS-T (1 h RT)
and incubated with Primary antibodies (mouse monoclonal anti alpha-actinin, (sigma), and rabbit polyclonal anti-troponin T, prior to washing and
incubation with Fab fragment anti-mouse 488, and anti-rabbit 568 (molecular probes). Images were acquired on an upright Leica SP5 confocal with
a 63× lens.
Human-based approaches to pharmacology and cardiology Page 7 of 12
by guest on January 4, 2016
D
ow
nloaded from
 
effects. Currently, various technologies such as multi-electrode ar-
ray (MEA), Ca2+ transient, impedance, and optical action potential
measurements are applied on hiPSC-CMs for their characterization.
Their potential has been highlighted by the CiPA initiative launched
by the FDA. On the other hand, drug-induced delayed and chronic
cardiotoxicity is one of the main risk for drug withdrawal from the
market. Therefore, Dr Kopljar described investigations of the acute
and delayed (5 days) effects of various oncological compounds on
hiPS-CMs using an impedance-based functional assay. Different
functional parameters such as beat rate, cell index and incidence
of arrhythmia-like events were evaluated, and indicate that the
hiPS-CMs can be used to detect different levels of acute and chronic
cardiotoxicity and could be valuable in drug safety.
In another industrial perspective, Dr Najah Abi-Gerges discussed
currently employed strategies in the pharmaceutical industry for
cardiotoxicity screening. He gave an overview of the issue pointing
out the high attrition rate of newmolecules during the iterative drug
discovery process: a significant number of these are caused by car-
diotoxicity.68 He highlighted the extent to which some safe new
drugs are not developed because of these potential concerns. The
new CiPA initiative attempts to address this issue.6 CiPA proposes a
paradigm based on screening new molecules against specific cardiac
ion channels combined with integrative computer modelling to pre-
dict the proarrhythmic potential of new drugs. This is subsequently
combined with non-rodent and early human clinical studies to as-
sess drug effects on QTc measurements. Dr Abi-Gerges highlighted
the need for further developing robust and predictive in silicomodels
that represent native myocyte physiology and the heart of healthy
volunteers and patients. Such models will predict acute and chronic
drug effects with high predictive value on ECG abnormalities other
than QT/proarrhythmia, heart rate, contractility, blood pressure,
and cardiac structure. Dr Abi-Gerges concluded by advocating
that scientists, modellers, regulators, and pharmaceutical industry
are currently well positioned to shape how future cardiac modelling
would positively impact drug development.
Arrhythmia mechanisms and biomarkers
A fourth session presented the use of experimental and computa-
tional methods for investigations into arrhythmia mechanisms and
biomarkers. Dr Stephen Harmer continued the theme of iPSC tech-
nologies, in this case for investigations on mechanisms of disease
pathogenesis in LQT1 using iPSC technology to model the heredi-
tary cardiac arrhythmia syndrome. Both heterologous (HEK293/
CHO-K1 cell expression systems) and iPSC-based cellular models
are used to investigate the underlying disease mechanisms, and a
comparison is conducted to evaluate whether the disease mechan-
isms are similar in both cell types. Results show differences on IKs
channel function and trafficking in heterologous systems for five
LQT1 patient mutations. The results are being modelled computa-
tionally to investigate the implications of IKs channel mutations on
action potential duration and morphology, and the penetrance of
the mutation in human cell populations such as those described in
the previous session.
Dr Sara Dutta presented a state-of-the-art multiscale human
whole heart computational framework to investigate arrhythmic ef-
fects of drugs and disease, and specifically hERG block in acute myo-
cardial ischaemia. The framework presented here consists of a
human anatomically based model with biophysically detailed re-
presentation of membrane kinetics including ionic current and con-
centration dynamics, as well as fibre orientation and ventricular
heterogeneity. The human multiscale model is parameterized using
experimental data, from voltage clamp at the ionic level to MRI scans
at the whole heart level. They provide a multiscale platform to dis-
sect and analyse specific ischaemic and arrhythmic processes with
high spatiotemporal resolution, which is not possible to obtain
through experiments alone, especially in human. The new insights
provided by the human model could help in the design of further ex-
perimental and clinical studies to improve patient risk stratification,
as well as decisions about drug dose during management of anti-
arrhythmic therapy. This study69 can be extended to explore the
mechanisms under different conditions, such as varying sizes and lo-
cations of the ischemic region, different drug compounds and their
multichannel effects, and inter-subject variability in ionic currents
and repolarization patterns. The presentation therefore highlighted
the power of human multiscale simulations using anatomically based
heart models to investigate safety and efficacy of pharmacological
action in lethal disease conditions.
Using a different computational approach, Dr Julien Oster pre-
sented advances on the computational detection of arrhythmia epi-
sodes in ECGs. The development of mobile technologies (mobile
phones, tablets, etc.) for health services (mHealth) is currently rap-
idly growing for two main reasons: (i) cost reduction and (ii) access
to resource-scarce communities.70 The importance for the auto-
matic or semi-automatic detection of arrhythmias on ECG record-
ings was highlighted in the presentation, given the simplicity of data
acquisitions and therefore the multiplication of such data. Manual
expert analysis would be more a burden for the clinicians than
help for the diagnosis of cardiovascular diseases. Machine-learning
approaches have been demonstrated to be a powerful tool for
such an analysis for several applications, such as atrial fibrillation
(AF) episodes or ventricular ectopic beat detection. Many Holter
softwares already require electrophysiologists or laboratory techni-
cians to annotate beats clustered together automatically. Llamedo
and Martinez71 recently suggested a technique requesting expert la-
belling of the clusters, outputted based on both morphological- and
rhythm-based features. Other techniques for rhythm classification
or AF episodes detection, based uniquely on the heart rhythm,
have also been presented, and are implemented in implantable
devices.72
Dr Oster’s presentation focused on two major arrhythmic types:
AF and premature ventricular contraction (PVC). A machine-
learning approach has recently been proposed, through the imple-
mentation of a Support Vector Machine73 on a mobile phone.74
PVC is another type of ventricular arrhythmia, identified as a pre-
dictor for mortality after myocardial ischaemia.75 The application
of an ECG morphology model-based Bayesian filtering76,77 was
shown to be effective for PVC detection.78
Ms Xin Zhou presented computational investigations into the io-
nic mechanisms underlying repolarization alternans in a population
of human ventricular models calibrated using in vivo recordings such
as those presented by Prof. Taggart. Previous research into cardiac
alternans has mainly been carried out in animals rather than in hu-
man. Ms Zhou presented the construction and calibration of a popu-
lation of over 2000 human ventricular cell electrophysiology models
B. Rodriguez et al.Page 8 of 12
by guest on January 4, 2016
D
ow
nloaded from
 
to mimic the action potential variability exhibited in in vivo electro-
physiological recordings from 41 patients.79 The in silico human ven-
tricular cell population is illustrated in Figure 5 and it was shown to
reproduce two types of alternans restitution curves also observed
in human in vivo recordings. By analysing the population of human
in silico models, she dissected the mechanisms underlying cardiac
alternans and how the complex interaction between sarcolemmal
currents and calcium dynamics contribute to the initiation and
maintenance of each alternans type. Therefore, in this presentation,
multiscale human in silico models were used to capture key repolar-
ization properties of in vivo recordings, to investigate the ionic
mechanisms underlying the occurrence of proarrhythmic repolari-
zation alternans and to identify potential anti-arrhythmic targets.
Dr Hua Rong Lu described a new, non-invasive and translational
biomarker—the index of cardiac electrophysiological balance
(iCEB, the ratio between QT and QRS)– in drug and ischaemia-
induced cardiac arrhythmias and in genetic LQT syndrome and Bru-
gada syndrome. Currently used biomarkers may not be adequate to
detect all types of drug-induced cardiac arrhythmias. Furthermore,
there is also a need for a new biomarker to detect cardiac risks in
patients with gene-defects in the heart such as LQT syndrome
and Brugada syndrome, in patients with heart failure and to detect
cardiac risks in sportsmen and women. iCEB was successfully
developed and introduced in 2013,80 it may detect potential risks
for drug-induced cardiac arrhythmias beyond LQT and Torsade
de Pointes. It may also a be better than currently used biomarkers
derived from animal models, such as the isolated rabbit left-
ventricular wedge model, because iCEB is also detecting additional
drug-induced potential cardiac arrhythmias by slowing conduction
and QT-shortening.80 iCEB was also found to be significantly in-
creased in patients in genetic LQT syndrome and significantly de-
creased in patients with Brugada syndrome.
New perspectives/beyond the human
heart
Dr Jean-Pierre Valentin introduced the background of compound
testing strategies in response to ICH guidelines and how the CiPA
initiative6,81–83 will develop a new non-clinical paradigm for cardiac
safety evaluation of new drugs by shifting the focus away from QT
prolongation to an assessment of proarrhythmia to mitigate against
the thorough QT study. The proposals would be to consider using
ion channel effects in tandem with utilizing the emerging technology
of in silico assessment and stem-cell-derived cardiomyocyte effects,
but not at the expense of clinical ECGs or an understanding of pharma-
cokinetics/pharmacodynamics.6 The initiative aims to deliver an imple-
mentation of recommendations initially by mid-2016 onwards;
however, this is dependent on community support in understanding
more about which experimental inputs, whichmodels and which levels
of predictive capacity are required.6 Finally, Valentin reminded the audi-
ence of a need to keep QT in perspective and to consider cardiac ef-
fects beyond QT as it only accounts for 4% of cardiac safety-related
drug attrition.84,85 Among the adverse events that are observed are ar-
rhythmia, tachycardia and changes in blood pressure.84,85
Dr Andre Ghetti set out the problem facing the development of
pharmaceutical drugs in the translation between in vitro and animal
studies to the clinical setting and the critical need to have stronger
models at the non-clinical phase for improving success and under-
standing of drug action. The approach that Dr Ghetti’s company Ana-
Bios will be taking is to use primary human tissue to derive cells that
can be used more reliably in predicting later clinical effects than in vitro
or animal studies can alone. This work is potentially to be used in par-
allel to the development of in silico approaches that are better in-
formed (parameterized) by the data being generated from these
isolated human primary cells. Taken together with a much improved
characterization of donors, includingmedical history, allows us to con-
sider the concept of incorporating real-world-type data into models.
Dr Rebecca Burton presented her recent work on developing a
cell culture model of neurally mediated arrhythmogenesis and
non-invasive optical imaging methods being pursued at Oxford.86,87
Biological models with varying degrees of complexity have been
developed to shed light on re-entrant arrhythmias and cardiac mono-
layers are one of the simplest models. The next stages of this research
is to pursue remote monitoring of in vitro cell cultures that would in-
crease experimental access, reduce the need to sacrifice additional
animals, and spur the adoption by other laboratories working in allied
research areas. There has been a proliferation of remote access plat-
forms that offer promising functionality. Remote access imaging offers
advantages to both ‘wet-lab’ and ‘dry’ experimentation (computa-
tional and mathematical modelling), and there is a need for platforms
which offer secure and reliable implementation.
Key challenges moving forward
In order to succeed in a programme of research and implementation
for drug discovery and testing that takes full advantage of the state of
the art in cardiovascular science, the workshop discussions identi-
fied five key challenges to be met
(1) Each of the human-based methodologies and techniques pre-
sented at the workshop has advantages and disadvantages, as
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Figure 5 Population of human ventricular action potential mod-
els calibrated using in vivo electrogram recordings. Each simulated
action potential in the population is generated using the O’Hara–
Rudy model with ionic conductances sampled in a wide range of
possible values. Calibration is then conducted using the in vivo elec-
trograms by selecting the models that yield action potentials with
properties such as action potential duration consistent with the
electrograms (red traces, accepted models), and rejecting those
that are outside range. In this figure, the action potential for the
original O’Hara–Rudy model is shown in black.
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each is able to provide specific forms of data and information,
while also leaving some gaps and therefore having limitations.
For example,
† while in vivo human experiments are in many respects the
best form of data, there are severe practical and ethical re-
strictions on acquiring this form of data;
† ex vivo human data suffer from many similar practical and eth-
ical restrictions, but also from the fact that the techniques
(such as cell isolation and voltage clamp) used can sometimes
bring about non-trivial effects that need to be compensated
for interpreting results;
† The utility of in vitro experiments on stem-cell-derived cardi-
omyocytes depends on the quality of the cell type produced
by differentiation and subsequent maturation. Currently, this
restricts their meaningful use to certain questions depending
on the functional integrity of key components which may
need to be proven rather than assumed to be intact.
(2) Computational approaches have the potential to bridge these
different methodologies, by extracting more value from the
data acquired from each, filling in gaps, and facilitating compari-
son and complementarity between them. This can be achieved
through computational approaches for data analysis (signal and
image processing to automatically capture and quantify proper-
ties, through the use of mathematics and computer science) and
through multiscale modelling, which allows for the exploration
of mechanisms of disease at different scales, and through making
predictions, in the form of new hypotheses for experimental
approaches to investigate further.
Computational modelling and simulation can meet their po-
tential only insofar as they interact in meaningful ways with ex-
perimental methodologies and techniques. From an industry
perspective, prediction would likely be predominantly used
early in drug discovery for prioritization and aiding decision-
making in compound selection. Later in drug discovery, the util-
ity is likely to shift to providing a mechanistic understanding of
in vivo results either to mitigate safety concerns or provide in-
sights into mechanisms for efficacy in, e.g. antiarrhythmia indica-
tions. If computational approaches are developed in a close
dialogue with experimental, clinical, and newly emerging digital
techniques, they act as mediators between the different data
forms and methodologies, and help to forge links between them.
(3) The success of the integration of complementary forms of data
and of methods depends upon achieving a true interdisciplinar-
ity of approaches and people. There is a need for expertise from
a wide spectrum of disciplines, together with the development
of skills at reaching across disciplines and for communicating
with researchers who are experts in different methods, and
who have different perspectives and priorities. New ways of
communicating are called for, as well as new approaches
to training next-generation researchers who are capable of
interdisciplinarity. In this respect, interdisciplinarity should
be widened to include social studies of science in order to
get a better grip on institutional, organizational, and social
barriers.
(4) Complementarity between different approaches requires input
and investment from the scientific community, who are key to
defining the criteria to be met for the assessment of drugs and
models, through establishing benchmarks, as well as through a
reconsideration of different methods and approaches to model
validation. A consensus for how the pharma and biotech indus-
try should respond is required and ideally supported by compel-
ling data that draw on a retrospective analysis supporting the
reasons to change. The motivation to change in pharma will
be aided by the proposed reduced requirements for thorough
QT studies and for the opportunity to reconsider compounds
that previously have been discontinued due to, e.g. QT pro-
longation. Implementation will be somewhat dependent upon
existing capabilities within the company, e.g. those capable of
ion channel screening assays, stem cell assays, and in silico mod-
elling. Even for those where this technology is established, the
choice of protocols and standards is key, especially given the
laboratory-to-laboratory variance in experimental measure-
ments. From the modelling perspective, which model and which
parameter set(s) need to be carefully defined; it would also be
necessary to consider CRO partners for these organizations
where ion channel screening, stem cell assays, and in silico mod-
elling are impractical.
(5) Finally, further measures to ensure a robust community formed
around strong partnerships across different sectors need to be
taken, including co-funding strategies that are targeted at devel-
oping the required research capability in people and organiza-
tions. Robust community formation requires attention to the
social elements of the community as well as the scientific re-
search questions.88 The further development of human-based
methods have ethical as well as scientific advantages, since
they aim to contribute to the 3Rs of animal experimentation;
however, they are associated with other forms of social, ethical
and legal constraints, and depend on successful engagement
with the wider non-scientific community.
Conclusion
In conclusion, the workshop identified key challenges in developing
an integrative human-based approach to pharmacology and cardi-
ology through the combination of in silico, in vivo, ex vivo, and in vitro
approaches. A clear outcome of the discussions is that these chal-
lenges must be tackled synergistically, through joint efforts and dis-
cussions across the sectors and stakeholders. A creative strategy
that is able to exploit complementarities between approaches
needs to be designed and implemented, in a concerted community
endeavour that is fully interdisciplinary and intersectoral.
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